A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.
about
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience.Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyCost-utility analyses of drug therapies in breast cancer: a systematic review.The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.Multi-gene classifiers for prediction of recurrence in breast cancer patients.Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis.GENE EXPRESSION PROFILING AND EXPANDED IMMUNOHISTOCHEMISTRY TESTS TO GUIDE SELECTION OF CHEMOTHERAPY REGIMENS IN BREAST CANCER MANAGEMENT: A SYSTEMATIC REVIEW.Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.Spotlight on the utility of the Oncotype DX® breast cancer assay.
P2860
Q30543788-28D4E080-1F4D-43C8-86A4-91FEED84DD36Q33560459-F6E89CFE-964C-4744-A455-16BBB69F9D5AQ34196301-5B9F86CF-3402-4F84-B057-4CB364E4289CQ35714516-2FCD17FF-515C-493B-B781-768DE44F26BFQ35915708-DE9A2C0A-AD04-4300-8C7A-0AD2BE788DD2Q36116276-A2B32F17-2A06-486E-8279-321799D9AE53Q36462893-9062E65B-8AC3-404B-A9DB-3FB80BCADF4FQ37233796-6E3A499B-8549-44DF-AF9C-D841482913C3Q37606937-C4E8013F-CAC0-4F97-885B-634EBD5C386FQ38232507-D1FE9DAD-407D-447A-AB94-080416228E43Q38362985-C53DC102-44E6-4227-9B93-6D3D81E5543EQ38540963-765AC19E-AFA6-47E0-8424-B8754E8AE4A8Q38795484-F88C9F01-524A-4C5B-AACB-EF431CA644DDQ41367403-73D932A6-2F41-4B4D-B377-130144EE785CQ52586260-9621C1F3-6BCF-46D9-B5D4-BDA09C4096B1Q52728983-59F52476-3605-421C-872F-789292647822
P2860
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
A prospective clinical utility ...... e node negative breast cancer.
@en
A prospective clinical utility ...... e node negative breast cancer.
@nl
type
label
A prospective clinical utility ...... e node negative breast cancer.
@en
A prospective clinical utility ...... e node negative breast cancer.
@nl
prefLabel
A prospective clinical utility ...... e node negative breast cancer.
@en
A prospective clinical utility ...... e node negative breast cancer.
@nl
P2093
P1476
A prospective clinical utility ...... ve node negative breast cancer
@en
P2093
B Czerkawski
C Lohrisch
C Yoshizawa
D N Ionescu
I Cromwell
J A Davidson
K A Gelmon
P304
P356
10.1016/J.EJCA.2013.03.009
P577
2013-04-20T00:00:00Z